Ophthalmic Pharmaceutical Pipeline*

Our single focus in ophthalmology enables exploration of novel therapies in dry eye, glaucoma,
uveitis, and wet AMD—therapies determined to challenge eye disease, one patient at a time

RETINAL DISORDERS

Retinal Disorders
UVEITIS

USA

Japan

Europe

Asia

Sirolimus
DE-109

WET AGE-RELATED MACULAR DEGENERATION

USA

Carotuximab
DE-122

Refractive Disorders

Refractive Disorders
MYOPIA

Asia

Atropine sulfate
DE-127

DRY EYE & CORNEAL DISORDERS

Dry Eye and Corneal Disorders
SEVERE KERATITIS WITH DRY EYE

USA

Asia

Ciclosporin
DE-076B

DRY EYE

China

Diquafosol sodium
DE-089

ALLERGIC CONJUNCTIVITIS

Japan

Epinastine hydrochloride
DE-114A

VERNAL KERATOCONJUNCTIVITIS

Europe

Canada

Asia

Glaucoma

Glaucoma
GLAUCOMA/OCULAR HYPERTENSION

USA

Japan

Sepetaprost
DE-126

Europe

Latanoprost
(Catioprost) DE-130A

USA

Asia

Japan

Omidenepag isopropyl
DE-117

China

Tafluprost / timolol maleate
DE-111

GLAUCOMA

USA

Europe

MicroShunt
DE-128

*Santen does not disclose early research activities. These are compounds in Development and are not for sale.